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R
NA interference (RNAi) oﬀers an at-
tractive means tosilence geneexpres-
sion with extraordinary speciﬁcity,
particularly for the subset of candidate ther-
apeutic gene targets that are considered
“undruggable”.
1 This capability is particu-
larly appealing for diseases with complex
genotypic alterations such as cancer. How-
ever, siRNA molecules are large (∼14 kDa),
highly anionic (∼40 negative charges), hy-
drophilic,andsusceptibletodegradationby
nucleases. Upon systemic administration,
naked siRNAs cannot penetrate into tumor
tissue, target extravascular cancer cells, or
cross cellular membranes to act in the cyto-
sol. Therefore, to bring RNA-based thera-
peutics into the clinic, one must improve
the pharmacokinetic properties of siRNA
and overcome several delivery barriers.
2,3
Approaches to target the delivery of
siRNA to tumor cells include lipophilic con-
jugations such as cholesterol,
4 attachment
to targeting moieties such as antibodies or
aptamers,
5,6 or encapsulation in polymer-
basedorliposomalcarrierstargetingtumor-
speciﬁcmarkers.
7Nonetheless,todate,none
of these approaches enable active penetra-
tion into the tumor parenchyma to achieve
gene silencing in epithelial tumor cells
wheregeneticalterations reside.Elsewhere,
cell penetrating peptides (CPP, also known
as protein transduction domains) such as
TAT and poly-arginine have been shown to
bring DNA- and RNA-based payloads into
thecytosol.
8WhileCPPsrepresentapromis-
ing class of siRNA carriers that rapidly pene-
tratesthecellmembrane,theylackreceptor
speciﬁcity; they bind to and are internalized
by cells via heparan sulfates and other
glycosaminoglycans in nearly all cell types
in vitro and in vivo.
9,10 Thus, an ideal siRNA
delivery system should possess two com-
plementary characteristics: it should eﬃ-
ciently penetrate tissues and cross cellular
membranes, but it should also be cell type-
speciﬁc by targeting only tumor cells while
sparing normal cells. Eﬀorts to enhance the
speciﬁcity of CPPs include attachment to
homing peptides or restriction of cargo
activity to speciﬁc cells.
11 13 However, the
development of receptor-speciﬁc CPPs has
been a highly empirical process: peptides
were tested one at a time without systema-
tic optimization of functional properties.
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ABSTRACT
Tumor-targeted delivery of siRNA remains a major barrier in fully realizing the therapeutic
potential of RNA interference. While cell-penetrating peptides (CPP) are promising siRNA
carrier candidates, they are universal internalizers that lack cell-type speciﬁcity. Herein, we
design and screen a library of tandem tumor-targeting and cell-penetrating peptides that
condense siRNA into stable nanocomplexes for cell type-speciﬁc siRNA delivery. Through
physiochemical and biological characterization, we identify a subset of the nanocomplex
library of that are taken up by cells via endocytosis, trigger endosomal escape and unpacking
of the carrier, and ultimately deliver siRNA to the cytosol in a receptor-speciﬁc fashion. To
better understand the structure activity relationships that govern receptor-speciﬁc siRNA
delivery, we employ computational regression analysis and identify a set of key convergent
structural properties, namely the valence of the targeting ligand and the charge of the
peptide, that help transform ubiquitously internalizing cell-penetrating peptides into cell
type-speciﬁc siRNA delivery systems.
KEYWORDS: siRNA delivery . tumor-penetrating peptides . cell-penetrating
peptides . LyP-1 . cancer therapy
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Consequently, tumor-speciﬁc delivery of siRNA by
CPPs is not routinely achieved.
Recently,anewclassofcell-internalizingandtumor-
penetrating peptides has been described which lever-
age a consensus C-terminal (R/K)XX(R/K) motif (the
CendR rule) to activate transvascular transport, cell
internalization, and parenchyma penetration.
14,15
Two peptides that both contain tumor-homing and
cryptic CendR motifs, iRGD (CRGDKGPDC) and LyP-1
(CGNKRTRGC), have been shown to signiﬁcantly im-
prove the delivery of small molecules, antibodies, and
nanoparticles to tumors.
16 Leveraging this discovery,
wehavepreviouslydevelopedtandempeptidesequences
bearingaconstanttumor-penetratingdomain(LyP-1) and
variable cell-penetrating/siRNA-binding domains to chap-
erone siRNA cargo deep into the parenchyma of ovarian
tumors in vivo and suppress a novel ovarian oncogene.
17
However,theintracellulartraﬃckingmechanismbywhich
siRNAs are delivered to tumor cells expressing speciﬁc
receptors remains incompletely understood. Furthermore,
the structure activity relationships that favor cell inter-
nalizationandmaximizegenesilencing,whilemaintaining
cell type-speciﬁc penetration have yet to be determined.
Here, we present a more in-depth analysis of cell
penetratingpeptidestobetterunderstandtheproperties
that govern receptor-speciﬁc siRNA delivery. We charac-
terized a library of tumor-penetrating nanocomplexes
formedbysiRNAsnoncovalentlyboundtotumor-speciﬁc
peptides bearing structurally distinct cell-penetrating
domains. A subset of nanocomplexes achieved func-
tional delivery of siRNA in a cell type-speciﬁc manner.
To gain quantitative mechanistic insights, we studied
the intracellular traﬃcking mechanisms by measuring
siRNA uptake, escape from endosomal entrapment,
and dissociation of siRNA from the carrier. To under-
standtherelationshipbetweenpeptidestructuralprop-
erties and receptor-speciﬁc siRNA delivery, we fused
datafromphysiochemicalcharacterizationswithregres-
sionmodelingtoderivestructure activityrelationships.
Twoproperties,thevalenceofthetumor-speciﬁcli ga nd
on the nanocomplex and peptide charge, are key con-
siderations when designing a siRNA delivery system
to knock down genes in a receptor-speciﬁc manner.
Speciﬁcally, we found that myr-TP-LyP-1 met the de-
sired material properties, condensed siRNA into nano-
complexes that are multivalent, and delivered siRNA to
human cancer cell lines in a receptor-speciﬁc fashion.
RESULTS AND DISCUSSION
Design and Characterization of Tandem Peptides. To de-
velop tumor-specific and cell-penetrating peptides for
siRNA delivery, we set the following design criteria:
the delivery system should noncovalently condense
siRNA in a single step, remain stable in physiologic
conditions, multivalently display homing peptides for
tumor-targeting, and readily dissociate once inside
the cytosol to enable siRNA incorporation into the
RNA-induced silencing complex (RISC). Toward this
goal, we synthesized a library of 9 tandem peptide
carriers composed of distinct cell penetrating domains
atthe NH2-terminusanda tumor-targeting/penetrating
CendR peptide, LyP-1 (CGNKRTRGC), at the C-terminus
(Figure1AandTable1).LyP-1homestotumorcellsand
tumor lymphatics via binding to its receptor p32, a
mitochondrial protein that is aberrantly expressed on
the surface of tumor cells and tumor-associated macro-
phages.
18,19 We generated N-terminally myristoylated
versions of each of the nine tandem peptides, since
myristoylation has been shown to enhance hydropho-
bicinteractionsandpeptideaffinitytolipidbilayerssuch
as the cell membrane.
20 The selection of cell-penetrating
domains included representatives of polycationic se-
quencesincludingoligoarginines,theHIVTATprotein,
21
and the HSV-1 tegument protein VP22;
22 as well as am-
phipathic CPPs such as penetratin
23 and Transportan.
24
To reduce the risk that siRNA complexation interfered
withreceptortargeting,thecell-penetratingandtumor-
targeting domains were separated by a four-glycine
spacer.
We found that tandem peptides readily condensed
siRNA into tumor-penetrating nanocomplexes (TPN)
in a one-step procedure (Figure 1B). To determine the
amount of peptide needed to fully encapsulate free
siRNAs into stable nanocomplexes, we mixed siRNA
with each tandem peptide at increasing molar ratios
in the presence of a dye (TO-PRO-3) that ﬂuoresces
when intercalated into double-stranded nucleic acids.
Upon particle formation, we observed a decrease in
dye ﬂuorescence likely due to steric exclusion of dye
binding to siRNA by peptides in the nanocomplex
(Figure 1B). Near-maximal (>95%) encapsulation of
siRNA occurred consistently at molar ratios between
1.6:1 and 20:1 (peptide-to-siRNA) for all peptides inthe
library. Since the positively charged CPP domain binds
the negatively chargedbackboneofthesiRNA,a higher
encapsulation ratio would result in increased num-
ber of tandem peptides per each siRNA molecule,
which in turn leads to a higher valence of LyP-1 in the
nanocomplex.
Using TEM and dynamic light scattering (DLS), we
observed that the majority of nanocomplexes have
hydrodynamicdiametersrangingfrom50to100nmin
water and from 200 to 400 nm in PBS, with a narrow
size distribution (polydispersity index < 0.2) (Figure 1C,
D). The zeta potential ranges from þ20 to þ40 mV
(Table 1). No signiﬁcant change in size was observed
when placed in mouse serum at 37  C (Supporting
Information, Figure S1A). Moreover, nanocomplexes
remainedintactforatleast24hinphosphate-buﬀered
saline (pH 7.1) at 37  Cas indicated by minimal change
in TO-PRO-3 ﬂuorescence (Figure 1E). To ensure that
TO-PRO-3 ﬂuorescence indeed corresponded to the
presenceofintactnanocomplexes,wedisruptednano-
complexes with a detergent and observed restoration
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of dye ﬂuorescence (Figure 1E). These results collec-
tivelysuggestthattandempeptidescannoncovalently
condense siRNA into stable nanocomplexes at deﬁned
molar ratios.
Cellular Uptake of Nanocomplexes. To effectively deliver
siRNA, the carrier should exhibit high cellular uptake
with minimal cytotoxicity. We examined a panel of
established, human cancer cell lines and identified
three (HeLa, MDA-MB-435, and OVCAR-8) that over-
express p32, the cognate receptor for the tumor-
penetratingdomain,LyP-1,onthecellsurface.Viability
of HeLa cells was not affected for the majority of
tandem peptides with the exception of 12R and 15R,
whose excess cationic charges may have contributed
to disruption of membrane integrity and reduction in
cell viability (Supporting Information, Figure S1B,S1C).
To gain insight into the siRNA delivery capabilities,
we used flow cytometry to assess the effect of NH2-
terminal myristoylation of the carrier on the cellular
uptake of siRNA. In OVCAR-8 human ovarian cancer
cells,themyristoylatedspeciesofthetandempeptides
were significantly more efficacious in delivering fluor-
escently labeled siRNA relative to their nonmyristoy-
latedcounterparts(Figure2A).Thischangemaybedue
to enhanced particle stability due to hydrophobic
interactions between myristoyl moieties, or enhanced
Figure 1. Design and characterization of tandem peptides. (A) Schematic representation of the tumor penetrating
nanocomplex, with siRNA (blue) noncovalently bound to tandem peptides composed of a cyclic tumor-penetrating domain
(LyP-1, green) and various cell-penetrating peptide domains (purple) separated by a 4-glycine spacer (gray). A subset of the
tandem peptides tested were N-myristoylated (myr, orange). Cell-penetrating peptide domains tested include representa-
tives from both polycationic and amphipathic CPPs. (B) Encapsulation of siRNA by tandem peptides. Tandem peptides were
mixed with siRNA at varying molar ratios, and the amount of siRNA encapsulated in nanocomplexes was determined by
measuring the ﬂuorescence of a nucleic-acid intercalating dye (TO-PRO-3) normalized to dye ﬂuorescence with siRNA alone.
(C)RepresentativeTEMofatandempeptide/siRNAnanocomplexformedinwaterandnegativelystainedwithuranylacetate;
scale bar = 100 nm. (D) Hydrodynamic size histograms of nanocomplexes in phosphate-buﬀered saline (PBS) from dynamic
light scattering measurements. (E) Stability of nanocomplexes in saline at 37  C, as measured by intercalation of TO-PRO-3
dye.Theﬁnaldatapoint(red,markedwithacircumﬂex(∧))representsdisruptionwith0.1%Triton-X100detergent.Errorbars
indicate standard deviation (SD) from three independent experiments.
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interactions between myristoylated peptides and
membrane lipids. To confirm that siRNA delivery was
indeed correlated with uptake of the carrier, we re-
peated the experiments with tandem peptides singly
labeledwithtetramethylrhodamine(TAMRA)andcom-
pared intracellular peptide fluorescence with siRNA
fluorescence for each peptide (Figure 2B). In general,
the relative cellular uptake of the carrier correlated
linearlywiththatofthesiRNAcargo.Shortoligo-arginine
CPPs such as 3R and 6R achieved poor siRNA delivery in
comparison to longer poly-arginines such as 12R and
15R, likely due to the lower number of cationic charges
available to bind the negatively charged siRNA back-
bone and provide sufficient charge shielding for mem-
brane translocation. Similar patterns in cellular uptake
were observed in MDA-MB-435 and HeLa cells (not
shown). Collectively, these results indicate that a subset
of tandem peptides can effectively carry siRNA payloads
into cell lines that express p32 on the surface; addition-
ally, N-terminal myristoylation of the peptide carrier
can further enhance siRNA delivery into the cell, likely
byimprovingpeptidelipophillicityandcellularuptake.
Next, we assessed whether siRNA delivery by nano-
complexesiscelltype-speciﬁc.Toconﬁrmp32receptor-
speciﬁcity, we utilized ﬂow cytometry to examine
siRNA uptake in the presence of a monoclonal anti-
body(mAb60.11)directedagainsttheNH2-terminusof
p32 polypeptide.
18 In OVCAR-8 cells, uptake of nano-
complexes bearing CPP domains such as TAT, 9R, 12R,
and 15R was unaltered in the presence of the antibody.
Incontrast,the p32 antibodyreducedsiRNAdelivery by
TP, 3R, 6R, and PEN nanocomplexes in a dose-dependent
manner by up to 80% (Figure 2C,D). Compared to cationic
CPPs suchas 12R and15R thatformed nanocomplexes
at a peptide-to-siRNA molar ratio of nearly 1:1, TP-, 3R-,
and6R-LyP-1nanocomplexeswereformedataratioof
atleast9:1,resultinginalargernumberofpeptidesper
each siRNA molecule, and thus a higher LyP-1 valence
inthenanocomplex.Sincemultivalentreceptor ligand
interactionsenhancespeciﬁcitythroughavidityeﬀects,
25,26
thehigherp32-aﬃnity(lowerIC50ofmAb)observedfor
this subset of nanocomplexes (TP, 3R, 6R) is attributa-
ble to multivalency eﬀects.
Gene Silencing with Nanocomplexes. We next set out to
determine the in vitro gene silencing activity of siRNAs
delivered by nanocomplexes. HeLa cells stably expres-
singadestabilizedgreenfluorescenceproteinreporter
(dGFP) were used as a model system for direct quanti-
fication of the RNAi response. Cells were treated with
siRNAagainstGFPboundtoeithertandempeptidesor
lipofectamine and analyzed by flow cytometry for GFP
knockdown. Consistent with previous findings that
myristoylation improves cellular uptake, myrisoylated
carriers were more efficient in delivering siRNA and
suppressing GFP expression than nonmyristoylated
ones (Figure 3A,B and Supporting Information,
Figure S2A). Six of nine tandem peptide carriers were able
to silence GFP expression by over 50%, as determined by
comparing the geometric means of the entire cell popu-
lation.ThedegreeofGFPsuppressioncorrelatedwiththe
dose of siRNA (Supporting Information, Figure S2B), was
detectable starting at 24 h, and was maintained through
at least 48 h after transfection (Figure S2C).
For tumor-speciﬁc siRNA delivery, an ideal system
shouldtargetthedeliveryofsiRNAtotumorcellswhile
sparing nontumor or essential cells. To quantitatively
TABLE 1. Structural Properties of Peptide/siRNA Nanocomplexes
name sequence
a diameter (nm)
b ζ-potential (mV)
c
3R (dR)3GGGGK(TAMRA)CGNKRTRGC 517.0 ( 33.9 7.8 ( 5.6
6R (dR)6GGGGK(TAMRA)CGNKRTRGC 364.3 ( 42.0 11.6 ( 8.6
9R (dR)9GGGGK(TAMRA)CGNKRTRGC 291.7 ( 21.2 ND
12R (dR)12GGGGK(TAMRA)CGNKRTRGC 175.5 ( 42.3 ND
15R (dR)15GGGGK(TAMRA)CGNKRTRGC 211.4 ( 18.9 ND
PEN RQIKIWFQNRRMKWKKGGGGK(TAMRA)CGNKRTRGC 259.0 ( 36.1 ND
TAT GRKKRRQRRRGYKGGGGK(TAMRA)CGNKRTRGC 175.3 ( 5.5 ND
TP GWTLNSAGYLLGKINLKALAALAKKILGGGGK(TAMRA)CGNKRTRGC 310.5 ( 61.2 ND
VP22 DAATATRGRSAASRPTERPRAPARSASRPRRPVDGGGGK(TAMRA)CGNKRTRGC 253.5 ( 6.5 ND
m3R myr-(dR)3GGGGK(TAMRA)CGNKRTRGC 209.0 ( 40.5 21.8 ( 5.0
m6R myr-(dR)6GGGGK(TAMRA)CGNKRTRGC 151.0 ( 11.1 27.3 ( 4.0
m9R myr-(dR)9GGGGK(TAMRA)CGNKRTRGC 207.8 ( 19.6 36.6 ( 7.1
m12R myr-(dR)12GGGGK(TAMRA)CGNKRTRGC 191.2 ( 17.9 27.6 ( 15.0
m15R myr-(dR)15GGGGK(TAMRA)CGNKRTRGC 377.2 ( 49.4 36.0 ( 7.5
mPEN myr-RQIKIWFQNRRMKWKKGGGGK(TAMRA)CGNKRTRGC 337.6 ( 54.9 29.0 ( 5.1
mTAT myr-GRKKRRQRRRGYKGGGGK(TAMRA)CGNKRTRGC 194.6 ( 43.6 35.8 ( 8.0
mTP myr-GWTLNSAGYLLGKINLKALAALAKKILGGGGK(TAMRA)CGNKRTRGC 343.6 ( 32.3 31.9 ( 3.7
mVP22 myr-DAATATRGRSAASRPTERPRAPARSASRPRRPVDGGGGK(TAMRA)CGNKRTRGC 233.0 ( 58.8 30.8 ( 4.8
aThe myr- preﬁx denotes NH2-terminal myristoylation. Peptide abbreviations are as follows: (dR)n = oligoarginine where n is the number of D-arginine residues; PEN =
penetratin; TAT = HIV TAT (48 60); TP = transportan; VP22 = HSV-1 VP22 protein.
bMean hydrodynamic size based on dynamic light scattering measurements. Errors
indicate SD from at least three separate measurements.
cZeta-potential of nanocomplexes. Errors indicate SD from at least three independent measurements. ND, not
determined.
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assess the ability of nanocomplexes to deliver siRNA in
a receptor-speciﬁc fashion, we measured the “ﬁtness”
ofeachcandidatenanocomplexasthenormalizedsum
of gene silencing eﬃciency and p32-receptor spec-
iﬁcity(normalized1/IC50ofmAb60.11)(Figure3C,D).In
particular, VP22 exhibits low ﬁtness because cellular
uptake was non-cell-type speciﬁc and gene knock-
down was also poor. By contrast, nanocomplexes
bearing polycationic CPP domains (12R and 15R) read-
ily penetrated cellular membranes and carried siRNA
into the cytosol; however, they doso ina non-cell-type
speciﬁc manner as the presence of excess cationic
charges likely abrogated receptor-speciﬁcity, resulting
inlowﬁtness.Incomparison, cellularuptakebyamphi-
pathic CPPs such as PEN and TP is blocked by a p32-
speciﬁc antibody, suggesting that the receptor-speci-
ﬁcity of the LyP-1 domain is retained; nevertheless, TP
nanocomplexes are much more eﬃcient than PEN in
suppressing gene expression. Indeed, the nanocom-
plex formed with myr-TP-LyP-1 has the highest ﬁtness
value of all carriers, owing to both potency in knock-
down (>50% suppression of GFP) and p32 receptor
speciﬁcity (lowest IC50 of mAb 60.11).
Intracellular Trafficking of Nanocomplexes. Our results
thus far have demonstrated that for a given tumor-
specific ligand, the tandem presentation of various
universally internalizing CPP domains can lead to
varying degrees of fitness. A subset of nanocomplexes
was found to be taken up in a p32 receptor-specific
fashion, and subsequently delivered siRNA to achieve
efficient gene knockdown. To better understand the
molecular properties that favored the conversion of a
ubiquitously internalizing peptide into a receptor-
specific siRNA delivery system, we next investigated
the intracellulartraffickingmechanismsbywhichnano-
complexes carry siRNA payloads into the cytosol.
We applied myr-TP-LyP-1 nanocomplexes carrying
siRNAs labeled with a near-infrared ﬂuorophore to
HeLa cells and visualized intracellular traﬃcking via
ﬂuorescence microscopy. Fluorescent siRNAs were
present in punctate vesicular structures consistent
with sequestration in endosomes (Figure 4A). To di-
rectly conﬁrm the intracellular localization of siRNAs,
nanocomplexes were applied to HeLa cells either ex-
pressing a marker of early endosomes (Rab5a) or pre-
labeled with a pH-sensitive marker of endolysosomes
Figure 2. Cellular uptake of nanocomplexes. (A) OVCAR-8 ovarian cancer cells were incubated with nanocomplexes carrying
siRNA labeled with a near-infrared ﬂuorophore (VivoTag-S750). Cellular uptake is assessed by ﬂow cytometry for both
nonmyristoylated and myristoylated tandem peptides. Error bars indicate SD from 4 to 6 independent experiments. (B)
CellularuptakeofTAMRA-labeledpeptides(blue)withVivoTag-S750-labeledsiRNA(red)inOVCAR-8cells.Errorbarsindicate
SD from 4 to 6 independent experiments. (C) Uptake by OVCAR-8 cells in the presenceof increasing concentrations of a p32-
speciﬁc monoclonal antibody (mAb 60.11). Uptake of nanocomplexes was normalized to that without antibody inhibition.
Error bars indicate SD from 6 independent experiments. (D) Representative histograms from ﬂow cytometry for cellular
uptake of myr-12R-LyP-1 (top, m12R) and myr-TP-LyP-1 (bottom, mTP), in the presence of indicated concentrations of mAb
60.11 (black and gray) or a IgG control (red).
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(Lysotracker). Fluorescently labeled siRNAs showed
colocalization with both markers, suggesting that
nanocomplexes carried siRNA payloads into the cell
via endocytosis and were initially sequestered in
endosomes.
We next sought to directly evaluate the ability of
nanocomplexes to disrupt the endosomal membrane
of HeLa cells and trigger the cytosolic release of cargo
by codelivery with Calcein, a membrane-impermeable
ﬂuorophore.
27 In the presence of Calcein alone or
with LyP-1 peptide lacking the CPP domain, a vesicular
distribution indicative of little or no endosomal escape
wasobserved(Figure4B,C).Bycontrast, diﬀuseCalcein
staining in up to 30% of cells suggestive of endosomal
escape was seen with 12R, 15R, and TP tandem pep-
tides (Figure 4B). Endosomal escape was carrier dose-
dependent (Supporting Information, Figure S3A) and
waspartiallydependentontheprotonspongeeﬀect,
28
as the escape eﬃciency correlated linearly with the
number of arginines. In addition, N-myristoylated pep-
tides were generally more eﬃcient in enabling Calcein
entry into the cytosol than their nonmyristoylated
counterparts, consistent with enhanced interactions
between myristic acid and membrane lipids on the
endosome that likely generate transient pores to allow
leakageofmolecules.
29 Asimilarpatternofendosomal
escape results was observed when OVCAR-8 cells were
examined (Supporting Information, Figure S3B).
To identify the traﬃcking pathways utilized by
nanocomplexes after endocytosis, we examined the
cellular uptake of myr-TP-LyP-1 nanocomplexes in the
presence of small molecule inhibitors that each blocks
acomponentoftheendocytosispathway.
30Nanocom-
plex uptake was signiﬁcantly decreased when treated
withamiloride,aninhibitorofmacropinocytosis,PDMP,an
inhibitor of lipid-raft mediated endocytosis, and deoxyglu-
cose,aninhibitorofATPbiosynthesis(SupportingInforma-
tion,FigureS3C).Incontrast,inhibitorsofactinpolymeriza-
tion,clathrin-mediatedendocytosis,orcaveolae-mediated
endocytosis did not interfere with cellular uptake.
To achieve gene knockdown, the carrier must ulti-
mately dissociate from the siRNA cargo after escaping
fromtheendosometoallowtheincorporationofsiRNA
into the RISC machinery. To ascertain whether the
carrier dissociates and releases siRNA subsequent to
endosomal escape, we measured the relative amount
ofsiRNAthatdissociatedfromthecarrieruponexposure
to endolysosomal pH (pH 4 6) via monitoring the
Figure 3. Nanocomplex-mediated receptor-speciﬁc gene silencing in vitro. (A) HeLa cells stably expressing destabilized GFP
were transfected with nanocomplexes carrying siRNA against GFP. The amount of GFP knockdown was determined by ﬂow
cytometry 24 h later. Lipofectamine was used as a positive control. Error bars represent SD from cumulative data of three
independentexperiments.(B)Representativehistogramsformyr-TP-LyP1nanocomplexescarryingGFP-speciﬁcsiRNA.Mock
treated cells are shaded in gray. (C) Receptor-speciﬁcity quantiﬁed as the concentration of p32-speciﬁc antibody to inhibit
nanocomplex uptake by at least 50% (IC50). Increasing concentrations of antibodies were added to cells for 1 h and
subsequently in the presence of nanocomplexes for 4 h. Percent inhibition of nanocomplex uptake was determined by ﬂow
cytometry.IC50 valueswere derived by ﬁtting a standardnormalized dose response curve for inhibitory binding eﬀects. (D)
The ﬁtness of each nanocomplex, as determined by the normalized sum of knockdown eﬃciency and p32-speciﬁcity.
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intercalation of TO-PRO-3 dye (Figure 4D). We ob-
served that long poly-arginine peptides such as 12R
and 15R did not readily release siRNA at low pH, likely
due to the large number of positively charged argi-
nines that retard the unpacking of siRNA. In compar-
ison, amphipathic CPP species that are less cationic,
such as PEN and TP, readily unpacked and dissociated
from siRNA at acidic pH. Taken together, these obser-
vations support a siRNA delivery mechanism that con-
sisted of receptor-mediated endocytosis mediated by
macropinocytosis and lipid-rafts, followed by escape
from endosomal entrapment, and release of siRNA at
acidic pH. Furthermore, factors such as peptide charge
can aﬀect the eﬃciency of nanocomplex unpacking,
Figure4. Intracellulartraﬃckingmechanismsofnanocomplexes.(A,Top)Fluorescencemicroscopyimagesofhumanovarian
cancer cell line (OVCAR-8) transfected with Rab5a (CellLight Early Endosomes-GFP) 24 h prior (Early), and subsequently
incubated with nanocomplexes carrying near-infrared ﬂuorophore-labeled siRNA for 1 h. Images were pseudocolored for
visualization: blue = DAPI; red = Rab5a; green = VivoTag-S750-siRNA. Co-localization of siRNA with the early endosomal
marker is in yellow. Scale bar, 10 μm. (A, Bottom) Fluorescence microscopy images of HeLa cells after 4 h treatment with
100 nM FITC-siRNA encapsulated in myr-TP-LyP-1 nanocomplexes, in the presence of 50 nM Lysotracker dye to label late
endosomes and endolysosomes (Late). Images are pseudocolored for visualization of colocalization: blue = DAPI; red =
Lysotracker; green = FITC-siRNA. Scale bar, 10 μm. (B) Tandem peptide carriers enable the delivery of Calcein, a membrane
impermeant dye, into the cytosol of HeLa cells. The mean percentage of cells displaying a uniform, cytosolic distribution of
Calcein per each ﬁeld of view was determined (n = 500 800 cells counted for each carrier). Error bars indicate SD from three
independent experiments. (/) p < 0.05; (///) p < 0.001. (C) Representative ﬂuorescence microscopy images of HeLa cells
treated with nanocomplexes þ Calcein (top) or Calcein alone (bottom) (green = Calcein). (D) Quantiﬁcation of the relative
amount of siRNA dissociated from the nanocomplex carriers at endolysosomal pH (pH = 4 6).
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which mayinturn aﬀect the availability of siRNAinside
thecytosoltobindtomRNAtranscriptsandparticipate
in RNAi-mediated gene silencing.
Understanding Structure Activity Relationships. Despite
the consistency of the trends described above, the
differentfitnessofnanocomplexcandidatescouldonly
be partially explained by differences in cellular uptake,
endosomal escape, and rate of nanocomplex dissocia-
tion. For example, the low fitness of PEN and VP22
peptides can be attributed to low cellular uptake and
endosomal escape activity, which resulted in poor
siRNA delivery into the cytosol that is available for RISC
loading. In contrast, nanocomplexes such as 12R, 15R,
and TP all showed high cellular uptake and endosomal
escape activity; however, they differ significantly in
fitness owing to differences in receptor-specificity.
Therefore, other structural features of TP lacking in
12Ror15Rmayalsodictatetheefficiencyandspecificity
of siRNA transfection. As the optimized formulation
likely resides withina muchbroader and morecomplex
structural and functional space, a systematic screening
ofcarrierstructuralparametersisneededtoidentifyand
understand key properties that could impact fitness.
To this end, we took a quantitative computational
approach to systematically identify carrier properties
that favored cell-type speciﬁc gene knockdown. We
hypothesized that the relationship between carrier
properties and ﬁtness is likely to be linear; therefore,
a linear regression approach that could establish a list
of relative weights of signiﬁcant model parameters
was used.
31 Speciﬁcally, we chose a regression model
to generate relationships between carrier ﬁtness;
the eﬃciency of cell type-speciﬁc gene knockdown
taken at two diﬀerent siRNA concentrations (100 nM
and 50 nM) and at two time points (24 and 48 h
post transfection);and carrier structural properties,
TABLE 2. Parameters Used in the Computational Analysis
a
concn (nM) time (h) diameter (nm) diameter error (nm) zeta (mV) zeta error (mV) LyP-1 valence peptide charge % K and/or R charge density
100 24 209 40.5 21.8 5 11.03 6.6 41.18 0.39
100 24 151 11.1 27.3 4 31.16 9.6 50 0.48
100 24 207.8 19.6 36.6 7.1 2.732 12.6 56.52 0.55
100 24 191.2 17.9 27.6 15 1.186 15.6 61.54 0.6
100 24 377.2 49.4 36 7.5 1.912 18.6 65.52 0.64
100 24 337.6 54.9 29 5.1 5.604 10.6 36.67 0.35
100 24 194.6 43.6 35.8 8 1.843 12.6 48.15 0.47
100 24 343.6 32.3 31.9 3.7 35.68 7.6 19.51 0.19
100 24 233 58.8 30.8 4.8 1.457 9.6 27.08 0.2
100 48 209 40.5 21.8 5 11.03 6.6 41.18 0.39
100 48 151 11.1 27.3 4 31.16 9.6 50 0.48
100 48 207.8 19.6 36.6 7.1 2.732 12.6 56.52 0.55
100 48 191.2 17.9 27.6 15 1.186 15.6 61.54 0.6
100 48 377.2 49.4 36 7.5 1.912 18.6 65.52 0.64
100 48 337.6 54.9 29 5.1 5.604 10.6 36.67 0.35
100 48 194.6 43.6 35.8 8 1.843 12.6 48.15 0.47
100 48 343.6 32.3 31.9 3.7 35.68 7.6 19.51 0.19
100 48 233 58.8 30.8 4.8 1.457 9.6 27.08 0.2
50 24 209 40.5 21.8 5 11.03 6.6 41.18 0.39
50 24 151 11.1 27.3 4 31.16 9.6 50 0.48
50 24 207.8 19.6 36.6 7.1 2.732 12.6 56.52 0.55
50 24 191.2 17.9 27.6 15 1.186 15.6 61.54 0.6
50 24 377.2 49.4 36 7.5 1.912 18.6 65.52 0.64
50 24 337.6 54.9 29 5.1 5.604 10.6 36.67 0.35
50 24 194.6 43.6 35.8 8 1.843 12.6 48.15 0.47
50 24 343.6 32.3 31.9 3.7 35.68 7.6 19.51 0.19
50 24 233 58.8 30.8 4.8 1.457 9.6 27.08 0.2
50 48 209 40.5 21.8 5 11.03 6.6 41.18 0.39
50 48 151 11.1 27.3 4 31.16 9.6 50 0.48
50 48 207.8 19.6 36.6 7.1 2.732 12.6 56.52 0.55
50 48 191.2 17.9 27.6 15 1.186 15.6 61.54 0.6
50 48 377.2 49.4 36 7.5 1.912 18.6 65.52 0.64
50 48 337.6 54.9 29 5.1 5.604 10.6 36.67 0.35
50 48 194.6 43.6 35.8 8 1.843 12.6 48.15 0.47
50 48 343.6 32.3 31.9 3.7 35.68 7.6 19.51 0.19
50 48 233 58.8 30.8 4.8 1.457 9.6 27.08 0.2
aFor linearregressionanalysis ofnanocomplex ﬁtness, the input parameters for the model includedconcentration (concn, nM), timeof transfection (time, h),hydrodynamic size
(diameter,nm;diametererror,nm),zetapotential(zeta,mV;zetaerror,mV),valenceofthetumor-penetratingligand(LyP-1valence),theoverallchargeofthepeptideatneutral
pH (peptide charge), percent of amino acids that is either lysine or arginine (%K and/or R), and the overall charge normalized by number of amino acids (charge density).
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including nanocomplex diameter, zeta potential, va-
lence of the tumor-penetrating ligand LyP-1, peptide
charge at physiologic pH, percent of lysines or argi-
nines in the peptide sequence and charge density
(Table 2). To generate the data for the model, we
screened every combination of structural parameters
to select ones that were linearly independent and
individually signiﬁcant (t test with p < 0.05). Measure-
mentsforeachparameterwerecenteredandscaledto
ensure that the value of the associated regression
coeﬃcient is a direct measure of parameter impor-
tance. The parameter subset that resulted in a model
that best matched the measured ﬁtness for each
individual nanocomplex was selected for further anal-
ysis (R
2 = 0.74, F(1,29) = 13.9065, p <1 0
 6) (Figure 5A).
Two structural properties, namely the valence of
the targeting ligand and the peptide charge, were found
to be signiﬁcant variables for explaining diﬀerences in
nanocomplexﬁtness(Figure5B).Namely,alterationsinthe
valenceofthetargetingligandorinpeptidechargewithin
the range of charges observed exert the largest inﬂuence
on cell type-speciﬁc knockdown by the nanocomplex.
Notably, the regression coeﬃcient for peptide charge
was the most negative, suggesting that lowering peptide
charge might further enhance nanocomplex ﬁtness. Con-
sistent with our previous observations that multivalency
favored high receptor-speciﬁcity, the regression coeﬃ-
cient for valence was the most positive, suggesting that
increasing LyP-1 valence could also improve ﬁtness.
To further validate the importance of LyP-1 valence
and peptide charge in inﬂuencing cell type-speciﬁcg e n e
knockdown, we separated all nanocomplex candidates
into two groups based on their measured ﬁtness values.
Accordingly, nanocomplexes with high ﬁtness (best ﬁt-
nessgroup)exhibitedsigniﬁcantlyhigherpeptidevalence
and lower peptide charge than those with low ﬁtness as
determined by one-way ANOVA (F(1,34) = 19.5, p <1 0
 4
andF(1,34)=7.12,p<0.01,respectively),trendsthatwere
consistent with regression coeﬃcients determined from
the model (Figure 5C). Similar analysis for other selected
parameters (concentration, diameter, zeta error, and
charge density) did not yield statistically signiﬁcant diﬀer-
ences(datanotshown).Inaggregate,quantitativeregres-
sion analysis enabled us to identify and validate two
carrier structural properties;the valence of the targeting
ligand and the peptide charge;that explained diﬀer-
ences in nanocomplex ﬁtness.
Quantifying the Multivalency Effect. Guided by the com-
putational results, we further quantified the receptor-
specificity and multivalency effects of the myr-TP-LyP-1
TPN. In four human cancer cell lines with varying p32
expression, we found that the uptake of TPN was en-
hanced relative to untargeted control nanocomplexes
(UCN) bearing a scrambled peptide (TP-ARAL), and yet
remained linearly correlated with surface p32 levels across
different cell lines (Figure 6A and Supporting Information,
Figure S4A,B). In contrast to LyP-1 peptides, TPN has a
higher affinity to cell surface p32, as demonstrated by the
lower measured EC50 (concentration to produce 50% of
maximal cellular binding) in two p32-expressing cell lines
(Figure 6B and Supporting Information, Figure S4C). The
apparent dissociation constant (KD) of TPN was found to
be 10 20 fold higher than that of LyP-1 (KD,TPN = 215 nM;
KD,LyP‑1=5.6μM),consistentwithmultivalentnanoparticle
systems reported elsewhere.
25 TPN uptake was saturated
at higher concentrations, which further supports the inter-
pretationthatnanocomplexesweretakenupinareceptor-
mediated manner (Supporting Information, Figure S4D).
To better understand how the number of LyP-1
peptides displayed on the TPN inﬂuenced cellular
binding, we synthesized nanocomplexes with a
Figure5. Computationalmodelingtoidentifycarrierstructural
properties that inﬂuence ﬁtness. (A) Least square regression
model used to predict carrier ﬁtness versus measured ﬁtness.
The model is able to ﬁt the data with R
2= 0.74. Each data point
represents the normalized ﬁtness of a particular nanocomplex
candidateataspeciﬁcsiRNAconcentrationandtimepointpost
transfection.(B)Regressioncoeﬃcientsofthestructuralproper-
tiesdeterminedtobesigniﬁcantinpredictingﬁtness.Thenano-
complexvalenceofthetargetingligandandthepeptidecharge
(black) have the highest impact on nanocomplex ﬁtness. (C)
Nanocomplex populations were separated into two groups
based on individual ﬁtness (best ﬁtness and worst ﬁtness). The
average LyP-1 valence of the nanocomplex (left) and peptide
charge (right) are calculated for each group and compared.
Consistent with regression results, signiﬁcant separations be-
tweenthegroupsconﬁrmedthepositiveimpactofvalenceand
the negative impact of peptide charge on ﬁtness. (//) p<0 . 0 1 ;
(////) p < 0.0001.
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mixture of TP-LyP-1 and TP-ARAL peptides. Mixed
nanocomplexes exhibited saturated uptake at a
peptide-to-siRNA ratio of at least 10:1 (Figure 6C). As
thedensityofLyP-1ligandsexceedstheamountofp32
available for binding, additional LyP-1 peptides will
likely not engage in receptor-mediated endocytosis
and uptake will likely be saturated. Taken together,
these results conﬁrmed that p32 expression dictated
siRNA delivery by multivalent nanocomplexes formed
with myr-TP-LyP-1 tandem peptides.
CONCLUSIONS
To design vehicles for cell type-speciﬁc siRNA deliv-
ery, there are several barriers the delivery system must
negotiate before achieving gene knockdown. These
include receptor-mediated cellular binding, internali-
zationbyendocytosis,escapefromendosomalseques-
tration into the cytosol, and ultimately, dissociation of
siRNAfromthecarrierforRISCincorporation.Eachstep
can inﬂuence the fate of the intracellular cargo, which
in turn aﬀects the receptor-speciﬁcity and eﬃciency of
gene knockdown. Here, we have taken a systematic,
quantitative approach to designing peptides and un-
derstanding their function in cell type-speciﬁc siRNA
delivery. To this end, we synthesized a library of
tandem peptides bearing a tumor-speciﬁc domain
and distinct cell-penetrating domains, and formed
nanocomplexes with siRNA through noncovalent in-
teractions.AsubsetofnanocomplexesdeliveredsiRNA
to human cancer cell lines that express the cognate
p32 receptor on the surface. We further evaluated the
mechanism by which nanocomplexes delivered siRNA
to the cytosol by characterizing cellular uptake, endo-
somal escape, and siRNA dissociation.
Comparative analysis of 18 tandem peptides re-
vealed that variations in structural properties had a
signiﬁcant impact on receptor-speciﬁcity and gene
silencingeﬃciency.Poweredbylinearregressionmod-
eling, we identiﬁed the valence of the targeting ligand
onthenanocomplexandtheoverallpeptidecharge as
key structural properties that favored cell-type speciﬁc
gene silencing. The analysis led to the identiﬁcation
of the myristoylated tandem peptide, myr-TP-LyP-1,
which condensed siRNA into multivalent nanocom-
plexes and eﬀectively delivered siRNA in a cell-type
speciﬁcmanner. Incomparison tosystems that require
localizedactivationofRNAinterference,TPN-mediated
siRNA delivery can seek out select cancer cells and
deliver therapeutics to deep-seeded tumors.
32 Precli-
nical studies utilizing nanocomplexes to systemically
deliver siRNA therapeutic to xenografts mouse models
are currently underway. This advancement suggests
that a systematic approach to the design of cell-
penetrating peptides is essential for optimizing
tumor-speciﬁc delivery of siRNA therapeutics for ther-
apeutic applications.
METHODS
Cell Lines. HeLa and MDA-MB-435 cells were cultured in
Dulbecco's modification of Eagle's medium (DMEM, purchased
from Invitrogen) with 10% bovine serum (Invitrogen), 5 IU
penicillin, and 5 μg/mL streptomycin. OVCAR-8, OVCAR-4, and
CaOV-3 cells were cultured in RPMI 1640 medium (Invitrogen)
with 10% fetal bovineserum (FBS, Invitrogen), 2mM glutamine,
Figure 6. Multivalencyeﬀects of the myr-TP-LyP1 TPN. (A) The
relationship between surface p32 levels and the cellular uptake
ofTPNcarryingsiRNA-VivoTag750incervical(HeLa),melanoma
(MDA-MB-435) and ovarian (OVCAR-8 and Caov-3) cancer cells
that express varying amounts of p32. Uptake was quantiﬁed
using ﬂow cytometry and normalized to that of a control nano-
complex (UCN). (B) Uptake of TPN versus monovalent LyP-1
peptide in MDA-MB-435 cells. Error bars indicate SD from three
independent experiments. (C) Uptake of nanocomplexes bear-
ing a mixture of TP-LyP-1 peptides and TP-ARAL peptides in
MDA-MB-435 and Caov-3 cells measured by ﬂow cytometry.
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5IUpenicillin,and5μg/mLstreptomycin.Allcellswerecultured
at 37  C with 5% CO2. OVCAR-4 and CaOV-3 cells were gener-
ously provided by Dr. William C. Hahn.
Peptides and siRNAs. The tandem peptides were synthesized
via standard FMOC solid-phase peptide synthesis and purified
by high-performance liquid chromatography at the MIT Bio-
polymers Core and Tufts University Core Facility. The peptides
were then cyclicized by bubbling air into 10 μM aqueous pep-
tide solutions for 24 h, followed by lyophilization and storage
at  20  C. The effect of cyclization was confirmed by mass spec-
trometry. siRNAs were obtained from Dharmacon, Inc. The se-
q u e n c e so fs i R N A s(5 0-30)a r e :s i GFP (GGCUACGUCCAGGAGCGCA).
Fluorescent Labeling of siRNA. siRNAs bearing 30-amine on the
sense strand was reacted with VivoTag S-750 amine-reactive
dye (Visen Medical, Inc.) for 1 h at 37  C. The reaction mixture
was then precipitated overnight at  20  C in 0.14 M NaCl and
70% ethanol, pelleted by centrifugation, washed, and air-dried.
This labeling process was repeated to yield approximately 3.6
fluorophores per siRNA duplex.
DLS and Zeta Potential. Peptide-siRNA nanocomplexes were
prepared by mixing siRNA in nuclease-free H2O (20 μM) with
each tandem peptide carrier (400 μM) at a molar ratio of 1:20
(siRNA:peptide) in
1/5 of final volume in PBS for 10 15 min at
room temperature. The hydrodynamic radii and zeta potential
of nanocomplexes were determined using the zeta-potential
and dynamic light scattering (DLS) instrument (Zetasizer-Nano,
Malvern, Inc.).
Nanocomplex Library Gene Silencing and Uptake. HeLa cells ex-
pressing destabilized GFP were cultured in 96-well plates to ca.
70 80%confluence.siRNA(0 100nM)wasmixedwith20-fold
molar excess of tetramethylrhodamine-labeled tandem pep-
tides in PBS for 10 15 min at room temperature and added
over cells for 4 6 h at 37  C, after which the cells were washed
extensively with PBS containing 10 U/mL heparin to remove
unboundnanocomplexesandthemediumwasreplaced.Trans-
fection with Lipofectamine RNAiMAX was performed in accor-
dance with the manufacturer's instructions. The cells were cul-
tured for an additional 24 72h before being examined by flow
cytometry, analyzed by gating for propidium iodide-negative
(live) cells.
To measure the cellular uptake of the TP-LyP1/siRNA nano-
complex, OVCAR-4, OVCAR-8, CaOV-3, and MDA-MB-435 cells
were plated 48 h prior in 96-well plates and allowed to reach at
least70%inconﬂuency.Nanocomplexeswereaddedat100nM
siRNA/2 uM peptide for 2 h at 37  C in serum-free DMEM. Cells
were then washed with PBS/heparin, trypsinized, and analyzed
by ﬂow cytometry (LSR II). For TP-LyP1 nanocomplex blocking
experiments with anti-p32 antibody, OVCAR-8 cells were pre-
incubated with anti-p32 polyclonal antibody at speciﬁed con-
centrations for 1 h at 37  C before nanocomplex treatment.
Endosomal Escape. HeLa and OVCAR-8 cells were plated 48 h
prior in 96-well plates and allowed to reach at least 70% in
confluency. Calcein (0.25 mM) dye was added with or without
various nanocomplex formulations (100nM siRNA) in complete
medium (DMEM with 10% bovine serum) for 1 h at 37  C. The
cells were then washed three times with PBS and visualized live
with a fluorescence microscope using the FITC filter. The number
of cells with efficient endosomal escape as indicated by a diffuse
cytoplasmic FITC fluorescence was counted from at least eight
randomly selected fields of view and normalized to the total
numberofcells(n=500 800cellspercarrierineachexperiment).
Western Blotting. Cells were washed three times with 4  C
PBS, lysed in RIPA buffer (Millipore) containing protease inhibitor
cocktail (Roche), subjected to electrophoresis on a 4 20% acryl-
amidegel(Bio-Rad),andtransferredtoapoly(vinylidenediluoride)
membrane. The membrane was probed with anti-R-tubulin anti-
bodies (Invitrogen) and polyclonal anti-p32 or anti-ID4 antibodies
(Abcam) and detected with secondary antibodies (IRDye 680 goat
antimouseIgGorIRDye800goatantirabbitIgG(Li-COR)).Theblots
were scanned using the Li-COR Odyssey infrared imaging system
and the band intensities were quantified using Image J (http://
rsbweb.nih.gov/ij/).
Inhibition of Endocytosis and Imaging. HeLa cells grown in
96-well plates at ∼70% confluence were incubated with small
molecule inhibitors for1hat37 C, followedbyincubation with
nanocomplexes containing both labeled peptide (2 μM) and
GFP siRNA (100 nM) for an additional hour at 37  C. The cells
were washed three times with cold PBS and were subsequently
trypsinized for flow cytometry analysis. To visualize the intra-
cellular trafficking of nanocomplexes along with endosomal
markers, Lysotracker Red DND-99 (Invitrogen) or CellLight Early
Endosomes-RFP (Invitrogen) was prior to the addition of nano-
complexes according to manufacturer's instructions.
Least Square Analysis. Least square analysis was performed
using a custom built program in Matlab. To determine impor-
tant structural parameters needed to predict fitness, we sequen-
tially tested each combination of input parameters (nchoosek in
matlab) and performed least-squares regression for each combi-
nation using the Matlab regstats function to fit the model and
assess the significance of the fit (F statistic provided by regstats)
and the significance of each individual parameter used in the
model (T statistics provided by regstats). Parameter choices that
ledtoFstatistics withp>0.05 orwhereanyoftheparametershad
T statistic with p > 0.05 were not considered for further analysis.
The program then checked that parameters do not suffer from
damaging collinearity, which can result in uninformative regres-
sion weights.
31 To this end, we computed the variance inflation
factor as VIF = 1/(1   Ri2), where Ri2 is the multiple correlation
coefficient of parameter iregressed ontheremainingparameters.
VIF values above 10 are thought to be indicators of damaging
collinearity.Parametersetsthatsufferedfromcollinearitywerenot
considered for further analysis. Finally, of the parameter sets that
yielded significant fits, using parameters that were individually
significant to the model and did not suffer from damaging
collinearity,weselectedthemodelwithhighestR2,alsomeasured
using the regstats function.
Statistical Analysis. Statistical analyses were performed using
built-in statistical functions in GraphPad Prism (GraphPad Soft-
ware). Tumor burden between different cohorts and averaged
fluorescence intensities from immunofluorescence staining,
and Western blots were analyzed using one-way ANOVA and
appropriate posthoc tests.
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